Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (GB:0A4C)
LSE:0A4C
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.36Last Year’s EPS
-0.34Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -35.68%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in Altimmune's pipeline with new INDs and a strong financial position. However, challenges such as increased expenses and a net loss, along with the retirement of a key executive, were noted.Company Guidance
During the Altimmune Fourth Quarter and Full Year 2024 Financial Results Conference Call, significant guidance was provided regarding the company's future plans and expected milestones. The company highlighted the completion of enrollment in the Phase 2b IMPACT trial for pemvidutide in NASH, with top-line data anticipated in Q2 2025. The trial's dual primary endpoints are NASH resolution and fibrosis improvement at 24 weeks. Altimmune plans to seek an end-of-Phase 2 meeting with the FDA in 2025, aiming to initiate a Phase 3 program in early 2026 if results are positive. The company also announced that two additional INDs for pemvidutide were cleared by the FDA, with Phase 2 trials expected to start in mid-2025. Financially, Altimmune reported total cash and investments of $132 million at the end of 2024, funding expected to support operations into the second half of 2026. R&D expenses for the year were $82.2 million, primarily driven by pemvidutide's development, while net loss totaled $95 million for 2024.Significant Progress in 2024
2024 was a year of significant progress for Altimmune, achieving milestones such as completing enrollment in the Phase 2b biopsy-based trial of pemvidutide in NASH. The company is on track for a top-line data readout in the second quarter of 2025.
New INDs and Phase 2 Trials
Altimmune submitted INDs for pemvidutide in two additional indications in Q4 2024, both cleared by the FDA. Phase 2 efficacy trials are set to start in mid-2025.
Strong Financial Position
Altimmune ended 2024 with $132 million in cash and investments, expected to fund operations well into the second half of 2026.
R&D Day Announcement
A virtual R&D Day is scheduled for March 13th, where additional indications and opportunities for pemvidutide will be disclosed.
No Safety Signals from FDA
The FDA identified no safety signals related to pemvidutide in over 500 subjects treated in prior studies.
---
GB:0A4C Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0A4C Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $6.68 | $6.68 | 0.00% |
| Nov 12, 2024 | $7.21 | $9.58 | +32.78% |
| Aug 08, 2024 | $5.60 | $6.39 | +14.09% |
| May 09, 2024 | $7.43 | $7.85 | +5.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Altimmune Inc (GB:0A4C) report earnings?
Altimmune Inc (GB:0A4C) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Altimmune Inc (GB:0A4C) earnings time?
Altimmune Inc (GB:0A4C) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Altimmune Inc stock?
The P/E ratio of Altimmune is N/A.
What is GB:0A4C EPS forecast?
GB:0A4C EPS forecast for the fiscal quarter 2025 (Q1) is -0.36.
---